Evaluation of the clinical and economic effectiveness of newborn screening programs for inborn errors of metabolism
https://doi.org/10.25557/2073-7998.2020.10.4-9
Abstract
The article summarizes the data on the clinical and economic evaluation of newborn screening programs for inborn errors of metabolism (IEM). Various approaches to the clinical and economic evaluation of the effectiveness of newborn screening programs, the impact of expanding screening programs by MS/MS on the budget are discussed.
About the Authors
N. L. Pechatnikova
Morozov Children’s Municipal Clinical Hospital of the Moscow City Health Department
Russian Federation
Russian Federation
E. Y. Zakharova
Research Centre for Medical Genetics
Russian Federation
Russian Federation
V. L. Izhevskaya
Research Centre for Medical Genetics
Russian Federation
Russian Federation
References
1. Мурзабаева С.Ш., Малиевский О.А., Климентьева М.М. Экономические аспекты неонатального скрининга на гипотиреоз. Проблемы эндокринологии 2006; (5):3-5
2. Матулевич С.А. Массовый скрининг новорожденных на наследственные заболевания как часть системы медико-генетического консультирования: Автореф. дисс. докт. мед. наук. М., 2009.
3. Prosser L.A., Grosse S.D., Kemper A.R. et al. Decision analysis, economic evaluation, and newborn screening: challenges and opportunities. Genet Med. 2013; 14(8): 703-712
4. Арустамян Г.Н. Клинико-экономический анализ и его роль в управлении качеством медицинской помощи. Государственное управление. Электронный вестник. 2011(29):1-13.
5. Ягудина Р.И., Куликов А.Ю., Серпик В.Г. Фармакоэкономика. М.: Феникс, 2018: 237 с.
6. Homedes, N.1996. The disability-adjusted life year (DALY) definition, measurement and potential use (English). Human capital development and operations policy working papers; no. HCD 68 Washington, D.C.: World Bank Group. http://documents.worldbank.org/curated/en/482351468764408897/The-disability-adjusted-life-year-DALY-definition-measurement-and-potential-use
7. Vos T., Flaxman A.D., Naghavi M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2163-96. doi: 10.1016/S0140-6736(12)61729-2.
8. Ягудина Р.И., Куликов А.Ю., Нгуен Т. Определение «порога готовности платить» в России, в Европейских странах и в странах СНГ. Фармакоэкономика. 2011; 4(1): 7-11
9. Merritt J.L. 2nd, Chang I.J. Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. 2000 Apr 20 [Updated 2019 Jun 27]. In: Adam M.P., Ardinger H.H., Pagon R.A., et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1424/
10. Hamers F.F., Rumeau-Pichon C: Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France. BMC Pediatr 2012, 12:60
11. Dyack S. Expanded newborn screening: Lessons learned from MCAD deficiency. Paediatr Child Health. 2004;9(4):241-243. doi:10.1093/pch/9.4.241
12. https://ru.wikipedia.org/wiki/Экономика_Франции
13. Tran K., Banerjee S., Li H., et al. Clinical efficacy and cost-effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry. Clin Biochem 2007 (40): 235- 241
14. Grosse S.D., Thompson J.D., Ding Y. et al. The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience. Milbank Q. 2016;94(2):366-391
15. Insinga R.P, Laessig R.H., Hoffman G.L. Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel. J Pediatr 2002;141:524-531
16. Pfeil J., Listl S., Hoffmann G.F. et al. Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis. Orphanet J Rare Dis 2013; 8: 167. https://doi.org/10.1186/1750-1172-8-167
17. Cipriano L.E., Rupar C.A. Zaric G.S. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model. Value Health. 2007;10(2):83-97. doi: 10.1111/j.1524-4733.2006.00156.x.
Review
For citations:
Pechatnikova N.L., Zakharova E.Y., Izhevskaya V.L. Evaluation of the clinical and economic effectiveness of newborn screening programs for inborn errors of metabolism. Medical Genetics. 2020;19(10):4-9. (In Russ.) https://doi.org/10.25557/2073-7998.2020.10.4-9
Views:
809
Email this article 